Meiyun Chen

Meiyun Chen

Auto-generated profile, based on publicly available information

Meiyun Chen

School of Pharmaceutical Sciences (Shenzhen), Sun Yat-sen University, Shenzhen, China, sysu.edu.cn

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2014 in Journal of Medical Microbiology
Verified
Journal Article
Closed access
DWDongguo Wang
Dongguo Wang
WHWei Hou
Wei Hou
JCJiayu Chen
Jiayu Chen
YMYonghua Mou
Yonghua Mou
LYLinjun Yang
Linjun Yang
MCMeiyun Chen
Meiyun Chen
Three Klebsiella pneumoniae isolates exhibiting high-level resistance to carbapenem were analysed by PCR, PFGE, gene mapping, plasmid conjugation and Southern blot hybridization using a bla KPC probe. In addition to the frequently reported bla KPC-2 and bla KPC-3 genes, a novel bla KPC-15 gene was identified in one of the isolates. The results of plasmid analysis and Southern blot hybridization revealed that the three bla KPC genes were located on transferable plasmids exhibiting three different patterns. The patterns A, B and C were observed in the genetic makeup of each individual plasmid, and all three structures contained ISKpn6-like and ISKpn8 transposons. The results of the gene mapping and hybridization experiments performed with the bla KPC probe demonstrated that the plasmids harboured the three genes at approximately the 85.0, 54.0 and 73.0 kb positions. The study concluded that carbapenem resistance in the three isolates was primarily due to the production of carbapenem-hydrolysing β-lactamase.

30 January 2026 in Journal of Immunology Research
Verified
Journal Article
Open access
ZFZhong Feng
Zhong Feng
RWRuixia Wei
Ruixia Wei
JTJunhao Tian
Junhao Tian
HLHui Li
Hui Li
HCHaobo Chen
Haobo Chen
MYMeicun Yao
Meicun Yao
In clinical practice, Hezi Qingyou Formula (HZQYF) has been observed to effectively alleviate clinical symptoms associated with gastri ulcers, though its precise mechanism of action remains unclear. To investigate the effects of HZQYF on gastric ulcers, we established a rat model of gastric ulcer and examined its impact on ulcer area, pathological changes, inflammatory cytokines, gastric repair factors, levels of T‐superoxide dismutase (SOD), and malondialdehyde (MDA), as well as metabolites in gastric tissue and feces. The results demonstrated that HZQYF significantly reduced the gastric ulcer area and promoted gastric tissue repair in rats. It downregulated the phosphorylation of P‐P38, P‐JNK1/2, and ERK1/2 proteins in the mitogen‐activated protein kinases (MAPKs) pathway, inhibited pro‐inflammatory cytokines such as interleukin (IL)‐6, IL‐1β, and tumor necrosis factor‐α (TNF‐α), enhanced the expression of gastric repair factors including vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), trefoil factor family 2 (TFF2), and prostaglandin E2 (PGE2), reduced MDA content, and increased the activity of the antioxidant enzyme T‐SOD, thereby suppressing inflammatory responses and ameliorating gastric mucosal damage. Metabolomic studies revealed that HZQYF effectively normalized 40 metabolites in gastric tissue through four key metabolic pathways and 39 metabolites in feces through five key metabolic pathways. Notably, it regulated taurine and hypotaurine metabolism, as well as phenylalanine metabolism, restoring metabolite levels to normal and ameliorating metabolic disorders in diseased rats. In conclusion, HZQYF promotes the healing of experimental gastric ulcers in rats through anti‐inflammatory effects, activation of gastric repair factors, and normalization of gastric tissue metabolites, suggesting its potential therapeutic role in the treatment of gastric ulcers.